DE69634045T2 - Antithrombotische diamine - Google Patents
Antithrombotische diamine Download PDFInfo
- Publication number
- DE69634045T2 DE69634045T2 DE69634045T DE69634045T DE69634045T2 DE 69634045 T2 DE69634045 T2 DE 69634045T2 DE 69634045 T DE69634045 T DE 69634045T DE 69634045 T DE69634045 T DE 69634045T DE 69634045 T2 DE69634045 T2 DE 69634045T2
- Authority
- DE
- Germany
- Prior art keywords
- pyrrolidinyl
- benzo
- compound
- phenyl
- ethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c1c(-c2cnc(*)cc2)[n]c2c1cc(*)c(*=C)c2 Chemical compound *c1c(-c2cnc(*)cc2)[n]c2c1cc(*)c(*=C)c2 0.000 description 9
- ZVFILTXILGPDSY-UHFFFAOYSA-N CCCCNCc(ccc(C(OC)=O)c1)c1OC Chemical compound CCCCNCc(ccc(C(OC)=O)c1)c1OC ZVFILTXILGPDSY-UHFFFAOYSA-N 0.000 description 1
- DSYIFITXYYFJJD-UHFFFAOYSA-N CCCc1cc(C(c2c(-c(cc3)ccc3O)[s]c3c2cccc3)=O)ccc1O Chemical compound CCCc1cc(C(c2c(-c(cc3)ccc3O)[s]c3c2cccc3)=O)ccc1O DSYIFITXYYFJJD-UHFFFAOYSA-N 0.000 description 1
- VYJRLTPIDBMGQP-ZPGRZCPFSA-N CCN(CC)[C@@H](CCCC1)[C@H]1Oc1ccc(Cc2c(-c(cc3)ccc3OCCN3CCCC3)[s]c3cc(OC)ccc23)cc1 Chemical compound CCN(CC)[C@@H](CCCC1)[C@H]1Oc1ccc(Cc2c(-c(cc3)ccc3OCCN3CCCC3)[s]c3cc(OC)ccc23)cc1 VYJRLTPIDBMGQP-ZPGRZCPFSA-N 0.000 description 1
- CNTPZYOIXANKPD-UHFFFAOYSA-N CCc(cc(Cc1c(-c(cc2)ccc2OCCN2CCCC2)[s]c2c1cccc2)cc1)c1OCCC1CCCCC1 Chemical compound CCc(cc(Cc1c(-c(cc2)ccc2OCCN2CCCC2)[s]c2c1cccc2)cc1)c1OCCC1CCCCC1 CNTPZYOIXANKPD-UHFFFAOYSA-N 0.000 description 1
- QNCNYJLSTAZMOZ-UHFFFAOYSA-N CN(C)CCOc(cc1)ccc1-c([s]c1c2)c(C(c3ccc(CN(C)C)c(OC)c3)=O)c1ccc2O Chemical compound CN(C)CCOc(cc1)ccc1-c([s]c1c2)c(C(c3ccc(CN(C)C)c(OC)c3)=O)c1ccc2O QNCNYJLSTAZMOZ-UHFFFAOYSA-N 0.000 description 1
- KQMNZHGWOXPPPR-UHFFFAOYSA-N CN(C)Cc(c(Br)c1)ccc1C(OC)=O Chemical compound CN(C)Cc(c(Br)c1)ccc1C(OC)=O KQMNZHGWOXPPPR-UHFFFAOYSA-N 0.000 description 1
- LSLHBKYTRRJGMU-UHFFFAOYSA-N CN(C)Cc(c(OC)c1)ccc1C(O)=O Chemical compound CN(C)Cc(c(OC)c1)ccc1C(O)=O LSLHBKYTRRJGMU-UHFFFAOYSA-N 0.000 description 1
- FUIQKDKFMPLJRL-JHOUSYSJSA-N CN(C)[C@@H](CCCC1)[C@@H]1Oc1ccc(Cc2c(-c(cc3)ccc3OCCN3CCCC3)[s]c3cc(O)ccc23)cc1 Chemical compound CN(C)[C@@H](CCCC1)[C@@H]1Oc1ccc(Cc2c(-c(cc3)ccc3OCCN3CCCC3)[s]c3cc(O)ccc23)cc1 FUIQKDKFMPLJRL-JHOUSYSJSA-N 0.000 description 1
- CREADFHAHZTKKQ-UHFFFAOYSA-N COc(cc1)ccc1-c1c(C(c(cc2)cc(Br)c2OC)=O)c(cccc2)c2[s]1 Chemical compound COc(cc1)ccc1-c1c(C(c(cc2)cc(Br)c2OC)=O)c(cccc2)c2[s]1 CREADFHAHZTKKQ-UHFFFAOYSA-N 0.000 description 1
- XNEFNRNSKNIFDJ-UHFFFAOYSA-N COc(cc1)ccc1-c1c(C(c(cn2)ccc2Cl)=O)c(cccc2)c2[s]1 Chemical compound COc(cc1)ccc1-c1c(C(c(cn2)ccc2Cl)=O)c(cccc2)c2[s]1 XNEFNRNSKNIFDJ-UHFFFAOYSA-N 0.000 description 1
- XRUQWQRBKIMQSF-UHFFFAOYSA-N COc(ccc(C(c1c(-c(cc2)ccc2OCCN2CCCC2)[s]c2cc(OCc3ccccc3)ccc12)=O)c1)c1OC Chemical compound COc(ccc(C(c1c(-c(cc2)ccc2OCCN2CCCC2)[s]c2cc(OCc3ccccc3)ccc12)=O)c1)c1OC XRUQWQRBKIMQSF-UHFFFAOYSA-N 0.000 description 1
- QZZPYILWKWAQRM-UHFFFAOYSA-N COc1cc([s]c(-c(cc2)ccc2OCCN2CCCC2)c2)c2cc1 Chemical compound COc1cc([s]c(-c(cc2)ccc2OCCN2CCCC2)c2)c2cc1 QZZPYILWKWAQRM-UHFFFAOYSA-N 0.000 description 1
- WQPBLQJNYKKBJL-UHFFFAOYSA-N COc1ccc(c(Cc(cc2)ccc2O[IH]C(CCCC2)C2N2CCCCC2)c(-c(cc2)ccc2OCCN2CCCC2)[s]2)c2c1 Chemical compound COc1ccc(c(Cc(cc2)ccc2O[IH]C(CCCC2)C2N2CCCCC2)c(-c(cc2)ccc2OCCN2CCCC2)[s]2)c2c1 WQPBLQJNYKKBJL-UHFFFAOYSA-N 0.000 description 1
- YJAWNOHRGROURO-UHFFFAOYSA-N Clc1cc(Cc2c(-c(cc3)ccc3OCCN3CCCC3)[s]c3ccccc23)ccc1CN1CCCC1 Chemical compound Clc1cc(Cc2c(-c(cc3)ccc3OCCN3CCCC3)[s]c3ccccc23)ccc1CN1CCCC1 YJAWNOHRGROURO-UHFFFAOYSA-N 0.000 description 1
- KKWHLXZINLDWGT-UHFFFAOYSA-N O=C(c1c(-c(cc2)ccc2OCCN2CCCC2)[s]c2cc(N=O)ccc12)c1ccc(CN2CCCC2)c(Cl)c1 Chemical compound O=C(c1c(-c(cc2)ccc2OCCN2CCCC2)[s]c2cc(N=O)ccc12)c1ccc(CN2CCCC2)c(Cl)c1 KKWHLXZINLDWGT-UHFFFAOYSA-N 0.000 description 1
- LURGLWNKYGZWTG-UHFFFAOYSA-N O=C(c1c(-c(cc2)ccc2OCCN2CCCC2)[s]c2ccccc12)c1cc(Cl)c(CN2CCCC2)cc1 Chemical compound O=C(c1c(-c(cc2)ccc2OCCN2CCCC2)[s]c2ccccc12)c1cc(Cl)c(CN2CCCC2)cc1 LURGLWNKYGZWTG-UHFFFAOYSA-N 0.000 description 1
- MBQNCBNTJCZPAO-UHFFFAOYSA-N Oc(cc1)cc2c1c(CC(C1)=CC=C(CN3CCCC3)C1[Ne])c(-c1ccc(CCC3CCCC3)cc1)[s]2 Chemical compound Oc(cc1)cc2c1c(CC(C1)=CC=C(CN3CCCC3)C1[Ne])c(-c1ccc(CCC3CCCC3)cc1)[s]2 MBQNCBNTJCZPAO-UHFFFAOYSA-N 0.000 description 1
- CQINZLPFWYLUTN-UHFFFAOYSA-N Oc(cc1)ccc1-c1c(C(c(cc2)ccc2OCCN2CCCCC2)=O)c2ccccc2cc1 Chemical compound Oc(cc1)ccc1-c1c(C(c(cc2)ccc2OCCN2CCCCC2)=O)c2ccccc2cc1 CQINZLPFWYLUTN-UHFFFAOYSA-N 0.000 description 1
- BSOZNAOIYPLDPI-UHFFFAOYSA-N Oc(cc1)ccc1-c1c(C(c2ccc(CCCN3CCCC3)cc2)=O)c(cccc2)c2[s]1 Chemical compound Oc(cc1)ccc1-c1c(C(c2ccc(CCCN3CCCC3)cc2)=O)c(cccc2)c2[s]1 BSOZNAOIYPLDPI-UHFFFAOYSA-N 0.000 description 1
- OVDQPZVXFBWBPM-UHFFFAOYSA-N Oc1ccc(c(Cc(cc2)ccc2OC(CCCC2)=C2[n]2cncc2)c(-c(cc2)ccc2OCCN2CCCC2)[s]2)c2c1 Chemical compound Oc1ccc(c(Cc(cc2)ccc2OC(CCCC2)=C2[n]2cncc2)c(-c(cc2)ccc2OCCN2CCCC2)[s]2)c2c1 OVDQPZVXFBWBPM-UHFFFAOYSA-N 0.000 description 1
- KSGBAIZRMHXEOZ-UHFFFAOYSA-N Oc1ccc(c(Cc(cn2)ccc2OC(CCCC2)C2N2CCCCC2)c(-c(cc2)ccc2OCCN2CCCC2)[s]2)c2c1 Chemical compound Oc1ccc(c(Cc(cn2)ccc2OC(CCCC2)C2N2CCCCC2)c(-c(cc2)ccc2OCCN2CCCC2)[s]2)c2c1 KSGBAIZRMHXEOZ-UHFFFAOYSA-N 0.000 description 1
- FZOPMGRMJRZJFX-DDKACPBQSA-N Oc1ccc2c(C(c(cc3)cc(F)c3O[C@@H](CCCC3)C3N3CCCCC3)=O)c(-c(cc3)ccc3OCCN3CCCC3)[s]c2c1 Chemical compound Oc1ccc2c(C(c(cc3)cc(F)c3O[C@@H](CCCC3)C3N3CCCCC3)=O)c(-c(cc3)ccc3OCCN3CCCC3)[s]c2c1 FZOPMGRMJRZJFX-DDKACPBQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US712095P | 1995-10-31 | 1995-10-31 | |
US7120P | 1995-10-31 | ||
US2825296P | 1996-10-09 | 1996-10-09 | |
US28252P | 1996-10-09 | ||
PCT/US1996/017995 WO1997025033A1 (en) | 1995-10-31 | 1996-10-30 | Antithrombotic diamines |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69634045D1 DE69634045D1 (de) | 2005-01-20 |
DE69634045T2 true DE69634045T2 (de) | 2005-05-19 |
Family
ID=26676549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69634045T Expired - Fee Related DE69634045T2 (de) | 1995-10-31 | 1996-10-30 | Antithrombotische diamine |
Country Status (9)
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2217373A1 (en) * | 1996-10-10 | 1998-04-10 | Michael John Martin | Benzo¬b|thiophene compounds, intermediates, formulations, and methods |
WO1998049160A1 (en) | 1997-04-30 | 1998-11-05 | Eli Lilly And Company | Antithrombotic agents |
CA2288224A1 (en) | 1997-04-30 | 1998-11-05 | Mary George Johnson | Antithrombotic agents |
WO1998049161A1 (en) | 1997-04-30 | 1998-11-05 | Eli Lilly And Company | Antithrombotic agents |
AU7170898A (en) | 1997-04-30 | 1998-11-24 | Eli Lilly And Company | Antithrombotic agents |
EP1011666A4 (en) | 1997-04-30 | 2004-03-31 | Lilly Co Eli | ANTITHROMBOTIC AGENTS |
DE69819539T2 (de) | 1997-05-01 | 2004-09-30 | Eli Lilly And Co., Indianapolis | Antithrombotische mittel |
US7008950B1 (en) | 1997-06-05 | 2006-03-07 | Takeda Chemical Industries, Ltd. | Benzofurans as suppressors of neurodegeneration |
US6017914A (en) * | 1997-09-03 | 2000-01-25 | Eli Lilly And Company | Benzo[b]thiophene compounds, intermediates, formulations, and methods |
US6284756B1 (en) | 1998-04-30 | 2001-09-04 | Eli Lilly And Company | Antithrombotic agents |
US6166069A (en) * | 1998-05-12 | 2000-12-26 | American Home Products Corporation | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
EP0997460B1 (en) * | 1998-10-28 | 2002-12-11 | Eli Lilly And Company | Benzothiophene compounds as antithrombotic agents and intermediates |
DE69914563T2 (de) | 1998-10-30 | 2004-12-16 | Eli Lilly And Co., Indianapolis | Azaindol derivate und ihre Verwendung als antithrombotische Wirkstoffe |
US6620837B1 (en) * | 1999-11-19 | 2003-09-16 | Eli Lilly And Company | Antithrombotic agents |
WO2002094268A1 (en) | 2001-05-22 | 2002-11-28 | Eli Lilly And Company | Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen |
DE60210283T2 (de) | 2001-05-22 | 2006-11-09 | Eli Lilly And Co., Indianapolis | 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren |
CA2469435A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
CN1668303B (zh) * | 2002-07-22 | 2010-10-27 | 伊莱利利公司 | 含苯磺酰基的选择性雌激素受体调节剂 |
US7296361B2 (en) * | 2003-07-31 | 2007-11-20 | University Of Pittsburgh | Measuring device and method of measuring |
US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
EA015104B1 (ru) | 2003-08-01 | 2011-06-30 | Мицубиси Танабе Фарма Корпорейшн | Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера |
NZ556686A (en) | 2005-02-14 | 2010-01-29 | Bionomics Ltd | Novel tubulin polymerisation inhibitors |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
DK2200606T3 (en) | 2007-09-10 | 2017-12-04 | Janssen Pharmaceutica Nv | PROCEDURE FOR THE PREPARATION OF RELATIONSHIP USED AS INHIBITORS OF SGLT |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
EP2488515B1 (en) | 2009-10-14 | 2017-01-04 | Janssen Pharmaceutica NV | Process for the preparation of compounds useful as inhibitors of sglt2 |
US20120115799A1 (en) | 2010-05-11 | 2012-05-10 | Wenhua Wang | Pharmaceutical formulations |
EA028946B1 (ru) | 2011-04-13 | 2018-01-31 | Янссен Фармацевтика Нв | Способ получения соединений для применения в качестве ингибиторов sglt2 |
US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
JP6047582B2 (ja) | 2011-12-15 | 2016-12-21 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換ベンゾチエニル−ピロロトリアジンおよび癌の処置におけるその使用 |
CN104136439B (zh) | 2012-02-23 | 2017-01-18 | 拜耳知识产权有限责任公司 | 取代的苯并噻吩基‑吡咯并三嗪及其用途 |
EP3260451A4 (en) | 2015-02-19 | 2018-07-18 | JNC Corporation | Liquid crystalline compound having benzothiophene, liquid crystal composition and liquid crystal display element |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
EP4108659A1 (en) | 2016-06-07 | 2022-12-28 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
AU2018239542C1 (en) | 2017-03-23 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3274213A (en) * | 1961-09-05 | 1966-09-20 | Upjohn Co | Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes |
US3293263A (en) * | 1963-12-09 | 1966-12-20 | Upjohn Co | Diphenylbenzocycloalkenes |
GB1456323A (en) * | 1974-06-06 | 1976-11-24 | Labaz | Benzothiophenes process for preparing them and pharmaceutical compositions containing the same |
US4001426A (en) * | 1974-10-17 | 1977-01-04 | Smithkline Corporation | Substituted benzofurans and benzothiophenes |
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
CA2073776A1 (en) | 1990-11-15 | 1992-05-16 | Joerg Stuerzebecher | Meta-substituted phenyl alanine derivatives |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
US5371091A (en) * | 1992-08-31 | 1994-12-06 | Bristol-Myers Squibb Company | Heteroaromatic amine thrombin inhibitors |
US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US5441965A (en) * | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting thrombin |
US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
US5523309A (en) * | 1995-03-10 | 1996-06-04 | Eli Lilly And Company | Benzofuran pharmaceutical compounds |
JPH10204082A (ja) | 1996-10-25 | 1998-08-04 | Eli Lilly & Co | 選択的エストロゲンレセプターモジュレーターとしての活性を有する置換されたベンゾ[b]チオフェン化合物 |
US5929090A (en) | 1997-09-12 | 1999-07-27 | Eli Lilly And Company | 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods |
-
1996
- 1996-10-30 JP JP52518397A patent/JP2002500618A/ja not_active Withdrawn
- 1996-10-30 DE DE69634045T patent/DE69634045T2/de not_active Expired - Fee Related
- 1996-10-30 CA CA002236007A patent/CA2236007A1/en not_active Abandoned
- 1996-10-30 EP EP96940354A patent/EP0863755B1/en not_active Expired - Lifetime
- 1996-10-30 WO PCT/US1996/017995 patent/WO1997025033A1/en active IP Right Grant
- 1996-10-30 ES ES96940354T patent/ES2233982T3/es not_active Expired - Lifetime
- 1996-10-30 AU AU77255/96A patent/AU7725596A/en not_active Abandoned
- 1996-10-30 AT AT96940354T patent/ATE284690T1/de not_active IP Right Cessation
-
1997
- 1997-04-30 US US08/846,647 patent/US6025382A/en not_active Expired - Fee Related
-
1999
- 1999-05-14 US US09/312,593 patent/US6251921B1/en not_active Expired - Fee Related
- 1999-08-05 US US09/369,416 patent/US6265575B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1997025033A1 (en) | 1997-07-17 |
ATE284690T1 (de) | 2005-01-15 |
EP0863755A4 (en) | 1999-01-20 |
ES2233982T3 (es) | 2005-06-16 |
US6025382A (en) | 2000-02-15 |
DE69634045D1 (de) | 2005-01-20 |
AU7725596A (en) | 1997-08-01 |
US6251921B1 (en) | 2001-06-26 |
EP0863755A1 (en) | 1998-09-16 |
JP2002500618A (ja) | 2002-01-08 |
EP0863755B1 (en) | 2004-12-15 |
US6265575B1 (en) | 2001-07-24 |
CA2236007A1 (en) | 1997-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69634045T2 (de) | Antithrombotische diamine | |
DE69828522T2 (de) | Antithrombotische mittel | |
US6090843A (en) | Benzothiophenes compounds which have useful pharmaceutical activity | |
US6060488A (en) | Benzothiophenes for treating estrogen deficiency | |
US6133458A (en) | Benzo[B]indeno[2, 1-D]thiophene compounds, intermediates, compositions, and methods | |
US6350774B1 (en) | Antithrombotic agents | |
DE69824410T2 (de) | Antithrombosemittel | |
DE60008430T2 (de) | Verbindungen mit antithrombotischer wirkung | |
US6284756B1 (en) | Antithrombotic agents | |
US6288105B1 (en) | Antithrombotic agents | |
US6133262A (en) | Antithrombotic agents | |
WO1998048798A1 (en) | Antithrombotic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |